Hemophilia A
Idogen about the conference in Boston and the plans ahead
Christina Herder, acting CEO of the biotechnology company Idogen, joined BioStock's studio to talk about the company's participation at the 6th...
Idogen strengthens fund for clinical study in 2023
The subscription period has now begun for Idogen's rights issue, which...
Idogen strengthens the board with Jan Holgersson
Idogen strengthens the board with Professor Jan Holgersson as...
Idogen's acting CEO comments on the share issue
Biotechnology company Idogen is in the clinical phase with...
First hemophilia patient enters Idogen's study
The first patient with hemophilia A has now...
Exciting times for Idogen's new chairman of the board
On September 6, an extraordinary general meeting was held in...
Idogen's CMO on the transformation to clinical phase for IDO 8
Recently, the biotechnology company Idogen announced that the company has received...
Idogen's acting CEO talks about plans for the fall
hristina Herder has been appointed as the new acting CEO...
Norwegian doctors prepare for Idogen's study
Biotechnology company Idogen is in full swing with preparations...
Principal investigator on Idogen's clinical study with IDO 8
Idogen recently announced that they have received approval...
BioStock Studio: Idogen approaches clinical trial
Cell therapy company Idogen is approaching the start of a clinical...
BioStock Studio: Idogen's CEO comments on the issue outcome and the next important steps
On Monday, Idogen presented the outcome of the rights issue which...